CTTI envisions a future where clinical trials are more efficient, inclusive, and impactful by 2030—setting a shared aspiration for everyone in the research ecosystem. While progress may unfold at different paces across regions, populations, therapeutic areas, and trial types, this vision serves as both a roadmap and a call to action. To support this effort, CTTI launched the Measuring Trials Transformation project, developing a streamlined Metrics Framework and identifying high-priority metrics to track progress toward trial transformation.

Guided by this vision, CTTI is shaping its priorities, encouraging widespread adoption of forward-thinking practices, and collaborating with individuals and organizations to drive meaningful advancements. 

While our vision applies broadly to clinical trials, CTTI’s efforts primarily align with the NIH definition—research studies that prospectively assign participants to one or more interventions (which may include placebos or controls) to evaluate their effects on health-related biomedical or behavioral outcomes. However, we anticipate that our work will also benefit other clinical studies, including those without prospective assignment. Recognizing that clinical trials exist within the broader landscape of evidence generation, we remain committed to fostering progress that enhances the accessibility, quality, and relevance of research worldwide.